When to intubate in GCS?

GCS ≤ 8 requires intubation for airway protection. The patient cannot protect their own airway at this level of consciousness. Motor score is the most prognostically important component.

What is the best initial fluid for sepsis resuscitation?

Lactated Ringer's (LR) is the preferred resuscitation fluid. The SMART trial (2018) showed balanced crystalloids reduced death, new renal failure, and persistent renal dysfunction compared to normal saline.

When to start vasopressors in septic shock?

Start norepinephrine (first-line vasopressor) if MAP remains < 65 mmHg after initial 30 mL/kg crystalloid resuscitation, or earlier if patient is profoundly hypotensive. Do not delay pressors to complete full fluid resuscitation.

Why can serum uric acid be normal during acute gout?

During acute inflammation, IL-6 increases renal urate excretion and redistributes urate from plasma to tissues. Up to 40% of acute gout flares have normal serum uric acid. Joint aspiration with polarized microscopy is needed for definitive diagnosis.

How do you distinguish lupus flare from infection in SLE?

Key clues: CRP is low/normal in flare but elevated in infection. Complement (C3/C4) drops in flare but is normal/elevated in infection. Procalcitonin is elevated in bacterial infection but normal in flare. Anti-dsDNA rises in flare, stable in infection.

What is the difference between DKA and HHS?

DKA features acidosis (pH 600), hyperosmolality (> 320), and minimal ketosis -typically in Type 2 DM. DKA requires insulin drip; HHS requires aggressive fluid resuscitation first.

When to give tPA in acute ischemic stroke?

IV alteplase (tPA) can be given within 4.5 hours of last known well time in eligible patients. CT head must rule out hemorrhage first. For large vessel occlusion, mechanical thrombectomy can be performed up to 24 hours with favorable imaging.

What antibiotics for community-acquired pneumonia?

Inpatient non-ICU: ceftriaxone + azithromycin. ICU: ceftriaxone + azithromycin (add vancomycin if MRSA risk). Outpatient healthy: amoxicillin. Outpatient with comorbidities: augmentin + azithromycin or respiratory fluoroquinolone. Duration: 5 days if clinically stable for 48 hours.

How to interpret iron studies?

Iron deficiency: low ferritin (< 30), high TIBC, low iron, low transferrin saturation (< 20%). Anemia of chronic disease: normal/high ferritin (acute phase reactant), low TIBC, low iron. A ferritin of 50-100 in an inflamed patient may still represent iron deficiency.

What is the correction rate for hyponatremia?

Correct sodium no more than 8 mEq/L in 24 hours to avoid osmotic demyelination syndrome (ODS). For symptomatic severe hyponatremia with seizures, give 3% hypertonic saline 100-150 mL bolus over 10-20 minutes. If overcorrected, use D5W + DDAVP rescue protocol.

When to start antibiotics in meningitis?

Within 30-60 minutes. Do NOT delay antibiotics for LP or CT. Draw blood cultures, start empiric antibiotics (vancomycin + ceftriaxone ± ampicillin if > 50 or immunocompromised), then perform LP when possible. Dexamethasone should be given before or with the first antibiotic dose.

DOACs vs warfarin in antiphospholipid syndrome?

DOACs are contraindicated in APS. The TRAPS trial (2018) showed rivaroxaban was inferior to warfarin with more thrombotic events in triple-positive APS patients. Warfarin with INR target 2-3 is the standard for APS, indefinitely.

How to manage scleroderma renal crisis?

ACE inhibitors (captopril) are life-saving -start immediately and titrate aggressively. Do NOT hold for rising creatinine. Steroids > 15 mg prednisone per day precipitate scleroderma renal crisis. ARBs are NOT a substitute -evidence is only for ACEi.

What are the 4 pillars of heart failure treatment?

Guideline-directed medical therapy (GDMT) for HFrEF: (1) ARNI or ACEi/ARB, (2) beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) MRA (spironolactone or eplerenone), (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). All four should be initiated and titrated to target doses.

RoundsRx

Dashboard

Overview

Recent

Rotations

Quick Reference

Antibiotic Guide Analgesia Guide Sedation Guide Bowel Regimen Electrolyte Replacement Pain Management & Conversions Drug Interactions Anticoag Reversal IV Fluid Guide Inotropes Guide Vasopressors Insulin Guide Code Blue & Rapid Response Procedures Guide ECG Interpretation Lab Interpretation Radiology Quick Ref GCS Pocket Card Admission Orders & I-PASS Landmark Trials

Tools

💎 Clinical Pearls 🧠 Pimp Me Quiz 🧮 Clinical Calculators 📰 What's New 🎓 Intern Survival Guide ✅ Rounding Checklists 🩺 Procedure Guides ⚡ Electrolyte Replacement 💧 IV Fluids Guide 🩸 Transfusion Guide 💓 ECG Pattern Guide 🧪 Lab Interpretation Guide 📱 QR Poster 🔗 Resources 🎙️ Channels & Podcasts 🎮 Medical Games 🏛️ Famous Cases 🎬 Media Library

ℹ️ About

Available offline

PulmonologyChronic

COPD -Chronic Management

Irreversible airflow obstruction (FEV₁/FVC < 0.70 post-bronchodilator). GOLD staging drives therapy. Inhaler selection matters -know the stepwise approach. For acute exacerbations requiring ICU management, see AECOPD (ICU).

↪

Also see: AECOPD (Acute Exacerbation, ICU) for inpatient management: NIV pathway, antibiotic selection, steroid burst, vent settings.

🔍 Overview

What changed in GOLD 2026 COPD Report (released January 2026): (1) Biologics codified for severe eosinophilic COPD -mepolizumab, benralizumab (anti-IL-5/IL-5R), and dupilumab (anti-IL-4Rα) for patients with frequent exacerbations and blood eosinophils ≥ 300 cells/μL despite optimized inhaler triple therapy. (2) ABE classification (introduced 2023) refined further -A (low symptom + low exacerbation), B (high symptom + low exacerbation), E (any exacerbations regardless of symptom). Old ABCD framework retired. (3) Triple therapy (LABA/LAMA/ICS) reserved for Group E with eos ≥ 300 OR persistent exacerbations on LABA/LAMA. ICS-without-LABA is not appropriate. Step-down to LABA/LAMA encouraged when eos low and stable. (4) Spirometry severity (GOLD 1-4) retained for FEV₁ % predicted; symptoms (CAT, mMRC) and exacerbation history drive treatment, not GOLD stage alone. (5) Smoking cessation -varenicline preferred, cytisinicline now available, combination NRT (patch + short-acting) emphasized. (6) Pulmonary rehab within 4 weeks post-exacerbation strongly emphasized -reduces 1-year mortality and rehospitalization.

Diagnosis

Spirometry: post-bronchodilator FEV₁/FVC < 0.70 confirms airflow obstruction
Symptoms: chronic dyspnea, cough, sputum production (≥ 3 months/year × 2 years = chronic bronchitis definition)
Risk factors: smoking (> 10 pack-years), alpha-1 antitrypsin deficiency (test in early-onset or non-smoker COPD), biomass fuel exposure

GOLD Severity (by FEV₁)

GOLD Stage	FEV₁ (% predicted)	Severity
GOLD 1	≥ 80%	Mild
GOLD 2	50–79%	Moderate
GOLD 3	30–49%	Severe
GOLD 4	< 30%	Very severe

GOLD Stage vs GOLD ABE -they answer two different questions. A common point of confusion. GOLD Stage 1-4 (FEV₁ % predicted) tells you how bad the airflow obstruction is -drives prognosis, LVRS / lung transplant eligibility, disability evaluations. GOLD ABE (symptoms + exacerbation history) tells you what treatment the patient needs -drives inhaler choice, biologic eligibility, post-exacerbation rehab triggers. Treatment is NOT driven by FEV₁ anymore. A patient with GOLD 1 (mild FEV₁) but frequent exacerbations is Group E and gets aggressive therapy; a patient with GOLD 4 but no exacerbations and low symptoms could be Group A on a bronchodilator alone. Rule of thumb: GOLD Stage → prognosis. GOLD ABE → inhaler.

GOLD ABE Groups (2023, refined in 2026)

The 2023 GOLD report simplified the old ABCD into ABE; the 2026 report refined the framework further (biologics codified for severe eosinophilic Group E, triple therapy step-down rules, ICS-without-LABA explicitly inappropriate). Assessment is based on symptoms + exacerbation history.

Group	Symptoms (mMRC / CAT)	Exacerbations	Initial Therapy
A	Low (mMRC 0–1, CAT < 10)	0–1 (not leading to hospitalization)	Bronchodilator (SABA PRN or LAMA or LABA)
B	High (mMRC ≥ 2, CAT ≥ 10)	0–1 (not leading to hospitalization)	LABA + LAMA combination
E (Exacerbator)	Any	≥ 2 moderate or ≥ 1 hospitalization	LABA + LAMA. Consider LABA + LAMA + ICS if eos ≥ 300.

💊 Stepwise Therapy

▶ How to Escalate COPD Therapy, Step by Step (tap to expand)

GOLD 2023-2026 framework: initial therapy is driven by the ABE group (symptoms + exacerbation history), NOT the spirometry stage (GOLD 1-4 still informs prognosis but no longer chooses the drug). The 2023 update collapsed the old C/D groups into a single E (exacerbator). Two things every COPD patient gets regardless of step: smoking cessation (the only intervention that slows FEV₁ decline and reduces mortality) and the full vaccine bundle (flu, PCV20, COVID, Tdap, RSV ≥ 60, Shingrix ≥ 50).

Step 1: Confirm diagnosis and grade severity

Check	What	Why
Confirm COPD	Post-bronchodilator FEV₁/FVC < 0.70 on spirometry	Symptoms alone misdiagnose. Pre-bronchodilator obstruction may reverse and represent asthma. Without spirometry, you'll over-treat reversible disease and under-treat fixed obstruction.
Grade airflow limitation	GOLD 1 (FEV₁ ≥ 80%), GOLD 2 (50-79%), GOLD 3 (30-49%), GOLD 4 (< 30%)	Informs prognosis and qualifies for some interventions (lung volume reduction, transplant), but does not drive initial drug choice.
Check eosinophils	Baseline CBC with diff	Eos < 100: avoid ICS (no benefit, pneumonia risk). Eos 100-299: ICS uncertain, use judgment. Eos ≥ 300: ICS is helpful, especially in exacerbators (key threshold).
Assess alpha-1 antitrypsin	Once in every COPD patient, especially < 45 yr, lower lobe disease, family history, or never-smoker	AAT deficiency is treatable with augmentation therapy. Missing it is missing a specific therapy. GOLD recommends one-time testing in every COPD diagnosis.

Step 2: Assign the ABE group

Group	Symptoms	Exacerbations in past year	Initial Maintenance
A	Low (mMRC 0-1 or CAT < 10)	0-1 moderate, no hospitalization	A bronchodilator (LAMA preferred, but any of SABA-PRN-only, LAMA, or LABA acceptable)
B	High (mMRC ≥ 2 or CAT ≥ 10)	0-1 moderate, no hospitalization	LABA + LAMA (2023 update upgraded from single bronchodilator to combined; better FEV₁ and symptoms)
E	Any	≥ 2 moderate, OR ≥ 1 hospitalization	LABA + LAMA; add ICS if eos ≥ 300 (initial triple therapy)

Symptom tools: mMRC scores dyspnea 0-4 (0 = only with strenuous exercise; 4 = too breathless to leave the house). CAT scores impact across 8 domains 0-40. Use either, not both. The point of the symptom score is to detect a B patient hiding among A patients, frequent silent under-treatment when only spirometry is checked.

Step 3: Follow up at 4-12 weeks → Review, Assess, Adjust

The GOLD cycle:

Review: symptoms (mMRC/CAT), exacerbations since last visit, inhaler technique (observed return-demonstration, ~70% of patients use them wrong), adherence.
Assess: if persistent dyspnea or exacerbations, why? Wrong device? Wrong drug? Missed comorbidity (HF, OSA, bronchiectasis)? Continued smoking?
Adjust: escalate, switch device, address comorbidity. Don't escalate without first verifying technique and adherence (the #1 reason for apparent treatment failure).

Step 4: Step up if persistent symptoms or exacerbations

Current Regimen	Problem	Step Up
LAMA or LABA monotherapy	Persistent dyspnea	LABA + LAMA (combined inhaler preferred for adherence)
LABA + LAMA	Persistent exacerbations, eos ≥ 300	Add ICS → ICS + LABA + LAMA triple (Trelegy, Breztri). IMPACT (2018) and ETHOS (2020) showed triple reduces exacerbations vs dual and ETHOS showed mortality benefit.
LABA + LAMA	Persistent exacerbations, eos < 100	Add roflumilast (PDE4 inhibitor) for chronic bronchitis phenotype with FEV₁ < 50%, or azithromycin 250 mg daily or 500 mg 3×/wk for ex-smokers. ICS unlikely to help here.
Triple therapy	Persistent exacerbations, eos ≥ 300	Add biologic (see Step 5)
Triple therapy	Persistent exacerbations, eos < 100, chronic bronchitis	Add roflumilast 500 mcg daily (REACT/RE2SPOND: ~17% exacerbation reduction). GI side effects rate-limit.
Triple therapy	Persistent exacerbations, frequent infections	Azithromycin 250 mg daily or 500 mg M/W/F. Check QTc and audiogram first (QT prolongation, ototoxicity). Most benefit in ex-smokers.

Step 5: Biologic add-on for severe eosinophilic COPD (GOLD 2026)

Eligibility: severe eosinophilic COPD with frequent exacerbations (≥ 2 mod or ≥ 1 hospitalization in past year) AND blood eosinophils ≥ 300 cells/μL despite optimized triple therapy. GOLD 2026 codified this pathway after BOREAS (2023) and NOTUS (2024).

Dupilumab (Dupixent) 300 mg SC q2 wk - IL-4Rα; preferred if elevated FeNO or atopy overlap.
Mepolizumab (Nucala) 100 mg SC q4 wk - IL-5; MATINEE/METREX (2024) ~21% exacerbation reduction.
Benralizumab (Fasenra) 30 mg SC q8 wk - IL-5Rα; q8 wk dosing advantage.

Expensive (~$30-40k/yr), prior auth required.

Step 6: Non-pharm interventions, layered at every step

Intervention	When	Why
Smoking cessation	Every visit, every active smoker	The only intervention that slows FEV₁ decline and reduces mortality. Combine pharmacotherapy (varenicline or NRT) with counseling.
Pulmonary rehab	Symptomatic patients (mMRC ≥ 2), and ALL within 4 weeks of an exacerbation hospitalization	Reduces hospital readmission ~30%, improves exercise tolerance, dyspnea, QOL. Single highest-yield non-pharm intervention after smoking cessation.
Long-term oxygen therapy	Resting PaO₂ ≤ 55 or SpO₂ ≤ 88%, OR PaO₂ 56-59 with cor pulmonale, polycythemia (Hct > 55%), or peripheral edema. ≥ 15 hr/day.	NOTT (1980): > 15 hr/day O₂ reduced mortality. Not for isolated nocturnal or exercise desaturation (LOTT 2016 showed no benefit there).
Home NIV (BiPAP)	Stable severe hypercapnic COPD (PaCO₂ ≥ 52) with nocturnal hypoventilation or recent post-exacerbation hospitalization	HOT-HMV (2017): home NIV reduced readmission/death 17% in post-exacerbation hypercapnic patients.
Lung volume reduction (surgical or endoscopic valves)	Severe upper-lobe-predominant emphysema with hyperinflation and low exercise tolerance despite GDMT	NETT (2003): surgery improved exercise capacity and survival in upper-lobe-predominant, low-exercise-capacity subset. Endoscopic valves (Zephyr) approved 2018 for selected patients.
Lung transplant	Refractory severe COPD, FEV₁ < 25%, hypercapnia, pulmonary HTN, BODE 7-10	End-stage when all other options exhausted. Refer early to a transplant center.
Vaccines	All patients	Influenza annually, PCV20 (or PCV15 + PPSV23), COVID-19, Tdap (then Td q10y), RSV ≥ 60, Shingrix ≥ 50. Reduces exacerbations and pneumonia.

Shortcuts that override the ladder

Scenario	Do This	Why
ASTHMA-COPD overlap (history of asthma, atopy, eos high, reversible component on spirometry)	ICS-containing regimen from the start (ICS+LABA, escalate to triple as needed)	ICS-naive treatment is dangerous in asthma. Treat as asthma overlap when in doubt; don't withhold ICS waiting for exacerbation history.
Frequent pneumonia on ICS	Step down to LABA + LAMA (drop the ICS), especially if eos < 100	TORCH and FLAME: ICS modestly raises pneumonia risk. If eos doesn't support ICS and patient gets pneumonia repeatedly, withdraw it. SUNSET (2018) showed safe ICS withdrawal in non-eos patients.
Persistent symptoms on optimized triple, eos < 100	Re-evaluate diagnosis: HF (BNP, echo), bronchiectasis (CT chest), pulmonary HTN, OSA, deconditioning, anxiety	Comorbidity drives "treatment-resistant COPD" more often than under-treatment. Don't stack more drugs onto the wrong diagnosis.
Patient using SABA > 2×/week	Step up maintenance therapy	SABA overuse is a marker of poorly controlled disease, mirrors the asthma SABA-overuse signal (AUSTRI, etc.).
Acute exacerbation (worsening dyspnea, sputum volume/purulence)	Add oral steroid burst (prednisone 40 mg × 5 days, REDUCE 2013), antibiotic if increased purulence or hospitalized, increase short-acting bronchodilators. See COPD Exacerbation.	Acute management is separate from chronic escalation. After resolution, reassess group and consider step up.
Hypercapnic respiratory failure (pH < 7.35)	BiPAP first, intubate only if NIV fails or contraindicated	Brochard 1995: NIV reduces intubation 65%. Hypoxic drive concerns are overblown, target SpO₂ 88-92% to avoid hyperoxic CO₂ retention without underventilating.
Alpha-1 antitrypsin deficiency	Standard COPD therapy PLUS IV augmentation therapy (Prolastin, Zemaira) if ZZ phenotype with COPD	Disease-modifying for AAT, slows FEV₁ decline. Refer to specialty center.
End-of-life / palliative phase	Add low-dose opioids for dyspnea, anxiolytics for air hunger, palliative care referral	Morphine 1-2 mg PO q4h PRN provides dyspnea relief without respiratory depression at low dose. Pulm rehab + GDMT only goes so far in end-stage disease.

Inhaler Therapy

Drug Class	Examples	When	Key Notes
SABA PRN RESCUE	Albuterol (ProAir/Ventolin) 2 puffs q4–6h PRN	All patients -rescue inhaler	Quick onset (5–15 min). If using > 2×/week → step up maintenance therapy.
LAMA 1ST LINE MAINTENANCE	Tiotropium (Spiriva) 18 mcg daily Umeclidinium (Incruse) 62.5 mcg daily	Group A (monotherapy) or as part of combination	Preferred first-line maintenance in COPD (unlike asthma where ICS is first). Reduces exacerbations. Once-daily dosing.
LABA 1ST LINE MAINTENANCE	Salmeterol (Serevent) 50 mcg BID Formoterol 12 mcg BID Indacaterol (Arcapta) 75 mcg daily	Monotherapy or combination	Long-acting bronchodilator. Never use LABA alone in asthma (but OK in COPD).
LABA + LAMA GROUP B/E	Umeclidinium/vilanterol (Anoro Ellipta) Tiotropium/olodaterol (Stiolto)	Group B (symptomatic), Group E (exacerbator)	Dual bronchodilation = backbone of COPD therapy. Better than either alone for FEV₁, symptoms, and exacerbation reduction.
ICS (add-on) SELECTIVE USE	Fluticasone, budesonide (always in combination with LABA ± LAMA)	Only if eosinophils ≥ 300 or frequent exacerbations despite LABA+LAMA	ICS is NOT first-line in COPD (unlike asthma). Increases pneumonia risk TORCH, 2007. Use blood eosinophils to guide: ≥ 300 → add ICS. < 100 → avoid ICS.
Triple: ICS + LABA + LAMA ESCALATION	Fluticasone/umeclidinium/vilanterol (Trelegy Ellipta)	Group E with eos ≥ 300 or persistent exacerbations on dual	IMPACT, 2018: triple reduced exacerbations by 15% vs LAMA+LABA and 25% vs ICS+LABA. ETHOS, 2020: also showed mortality reduction. Best evidence for triple in high-eos exacerbators.
Biologics NEW 2026	Mepolizumab (Nucala) 100 mg SC q4 wk Benralizumab (Fasenra) 30 mg SC q8 wk Dupilumab (Dupixent) 300 mg SC q2 wk	Severe eosinophilic COPD with frequent exacerbations AND blood eos ≥ 300 cells/μL despite optimized triple therapy	GOLD 2026 codified biologic add-on for severe eos COPD. Mepolizumab and benralizumab target IL-5 / IL-5R; dupilumab targets IL-4Rα (used in eos COPD with elevated FeNO or atopy overlap). BOREAS, 2023 · NOTUS, 2024 · MATINEE, 2024. Expensive ($30-40k/yr) -prior auth required.

Vaccinations -All COPD Patients

Influenza -annually
Pneumococcal -PCV20 (Prevnar 20) or PCV15 + PPSV23
COVID-19 -per current guidelines
Tdap -if not previously received, then Td booster q10y
RSV -for adults ≥ 60 (shared clinical decision)
Zoster (Shingrix) -if ≥ 50

📋 On Rounds

Why is ICS not first-line in COPD the way it is in asthma?

COPD inflammation is primarily neutrophilic (driven by CD8+ T cells, neutrophils, macrophages) and relatively steroid-resistant. Asthma inflammation is eosinophilic (Th2-driven, mast cells, eosinophils) and highly steroid-responsive. ICS in COPD adds modest exacerbation reduction but significantly increases pneumonia risk TORCH, 2007.

When do you prescribe home oxygen in COPD?

Only for severe resting hypoxemia: PaO₂ ≤ 55 mmHg or SpO₂ ≤ 88% at rest on room air (or PaO₂ 56–59 with evidence of cor pulmonale or polycythemia). Must be measured when clinically stable, at rest, on room air. NOTT, 1980 showed mortality benefit for continuous O₂ (> 15 h/day).

What changed from GOLD ABCD to ABE?

The 2023 GOLD update merged groups C and D into a single group E (Exacerbator). Previously, C = low symptoms + frequent exacerbations, D = high symptoms + frequent exacerbations -but they had the same initial treatment (LABA+LAMA ± ICS), so the distinction was clinically unnecessary. Now: A = low symptoms/low exacerbations, B = high symptoms/low exacerbations, E = any symptoms with ≥ 2 moderate or ≥ 1 hospitalized exacerbation.

When do you prescribe long-term oxygen therapy (LTOT) in COPD and what's the evidence?

Indications for LTOT (≥ 15h/day): (1) Resting PaO₂ ≤ 55 mmHg or SpO₂ ≤ 88%, (2) PaO₂ 56-59 with evidence of cor pulmonale, polycythemia (Hct > 55%), or RHF. Evidence: NOTT, 1980 and MRC, 1981 showed LTOT ≥ 15h/day reduces mortality in COPD with severe resting hypoxemia. Continuous O₂ (> 18h/day) was better than nocturnal-only.

Case 1: GOLD Group E Frequent Exacerbator

67M with COPD, 3 exacerbations in the past year (Group E), FEV₁ 45% (GOLD 3), blood eosinophils 320 cells/μL, currently on Tiotropium (Spiriva) monotherapy. Presents for optimization. Step up to triple therapy: Fluticasone furoate/Umeclidinium/Vilanterol (Trelegy Ellipta), eosinophils ≥ 300 supports ICS addition per GOLD 2023. Add Roflumilast (Daliresp) 500 mcg daily given FEV₁ < 50% + chronic bronchitis (reduces exacerbations by 15–20%). Refer to pulmonary rehab. Continue Albuterol PRN rescue. Reassess eosinophils and PFTs in 3 months.

Case 2: Stable COPD with Dyspnea, Undertreated

72F with known COPD, GOLD Group B (FEV₁ 55%, mMRC 2, CAT score 14), using only Albuterol (ProAir) PRN. No hospitalizations. Dyspnea limits daily activities. Initiate LABA/LAMA combination: Umeclidinium/Vilanterol (Anoro Ellipta) once daily, dual bronchodilation is the backbone for Group B with high symptom burden. Assess and correct inhaler technique at every visit (70–80% use inhalers incorrectly). Check SpO₂ at rest; if ≤ 88%, initiate supplemental O₂ ≥ 15h/day. Reinforce smoking cessation and ensure vaccinations (PCV20, influenza, RSV, COVID-19) are current.

Case 3: COPD-Asthma Overlap (ACO)

58M, 30 pack-year smoking history, childhood asthma diagnosis, now with fixed airflow obstruction on PFTs but partial reversibility (post-BD FEV₁ improves > 12% and 200 mL). Blood eosinophils 450 cells/μL. ICS-containing regimen is mandatory, never LABA monotherapy in ACO (asthmatic component → LABA alone increases mortality per SMART trial). Start triple therapy: Budesonide/Glycopyrrolate/Formoterol (Breztri Aerosphere). If eosinophilic disease remains uncontrolled despite maximum inhaled therapy, consider add-on biologic: Dupilumab (Dupixent) targets IL-4/IL-13 and has FDA approval for uncontrolled COPD with eosinophilic phenotype.

📣 Sample Presentation

One-Liner

"Mr. Williams is a 66-year-old with COPD (GOLD stage II, FEV₁ 62%, Group E -2 exacerbations last year), currently on tiotropium only. Here for medication optimization."

Key Points to Cover on Rounds

COPD GOLD II, Group E (≥2 exacerbations/year). Current: LAMA only (tiotropium). Undertreated. Recommended per GOLD 2024: escalate to triple therapy (LAMA + LABA + ICS) given eosinophils 320 (>300 supports ICS). Prescription: fluticasone furoate/umeclidinium/vilanterol (Trelegy) 100/62.5/25 one puff daily. Rescue: albuterol PRN. Azithromycin 250 mg MWF for exacerbation prevention (eosinophils >100 + frequent exacerbations). Vaccinations: pneumococcal (PCV20), flu, COVID, RSV -all updated. Pulmonary rehab: referred. Smoking: quit 3 years ago -reinforced. LDCT screening: current. Plan: PFTs in 3 months, reassess.

🧪 Workup

Workup -Pulmonary Nodule & Lung Cancer Screening

Topic-specific workup details are in the Overview and Management tabs.

💊 Medications

Medications -Pulmonary Nodule & Lung Cancer Screening

Medication details are in the Management tab with evidence-based dosing and trial citations.

⚡ Summary

Summary

GOLD Classification

Spirometry: GOLD I-IV by FEV₁ %. Group A/B/E by symptoms + exacerbation history. Group E (≥ 2 exacerbations/year) = most aggressive treatment.

Inhaler Ladder

Group A: SABA PRN. Group B: LABA or LAMA. Group E: LAMA + LABA + ICS (triple therapy) if eos ≥ 300. If eos < 300: LAMA + LABA without ICS.

Exacerbation Rx

Prednisone 40 mg × 5 days + antibiotics (azithromycin or doxycycline) if purulent sputum + bronchodilators + O₂ target 88-92%.

LTOT

SpO₂ ≤ 88% or PaO₂ ≤ 55 at rest → O₂ ≥ 15h/day reduces mortality [NOTT, MRC]. Moderate desaturation (89-93%): no benefit LOTT, 2016.

Exacerbation Prevention

Triple therapy (ICS/LABA/LAMA), azithromycin 250 MWF, roflumilast (eos ≥ 300), pulmonary rehab, smoking cessation, vaccinations.

Vaccines

PCV20, flu (annual), COVID, RSV (≥ 60), Tdap. All reduce exacerbation-related hospitalization.

⚡ Management

Management -COPD -Chronic Management

See the Management section above for the full treatment algorithm with evidence-based recommendations and trial citations.

📄 One Pager

Pulmonology · One Pager

COPD

GOLD staging by FEV₁ + symptoms + exacerbations. Triple therapy (ICS/LABA/LAMA) for Group E. LTOT if SpO₂ ≤ 88%. Pulmonary rehab reduces hospitalizations. Vaccinations for all.

🧪 Classification

Spirometry: GOLD I-IV by FEV₁ %. Group A: few symptoms, 0-1 exacerbations. Group B: more symptoms, 0-1 exacerbations. Group E: ≥ 2 exacerbations/year or ≥ 1 hospitalization.

🚨 Acute Exacerbation

Prednisone 40 mg × 5 days + antibiotics (azithromycin or doxycycline if purulent sputum) + bronchodilators + O₂ target 88-92% (avoid O₂-induced hypercapnia). BiPAP for hypercapnic respiratory failure.

💊 Chronic Management

Group A: SABA PRN. Group B: LABA or LAMA. Group E: LAMA + LABA + ICS (triple, if eos ≥ 300). Azithromycin 250 MWF (exacerbation prevention). LTOT if SpO₂ ≤ 88% [NOTT, MRC]. Pulmonary rehab. Vaccinations.

💊 Key Drugs

Trelegy ElliptaICS/LAMA/LABA (triple)

Tiotropium18 mcg daily (LAMA)

Prednisone40 mg × 5d (exacerbation)

Azithromycin250 mg MWF (prevention)

⚠️ Pitfalls

O₂ target > 92% in COPD (risk of hypercapnia -target 88-92%)
ICS without LABA (ICS monotherapy not recommended in COPD)
Missing OSA overlap (common, worsens outcomes)
Not referring for pulmonary rehab (most effective non-pharmacologic intervention)